A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DRUG: Taxol|DRUG: Cisplatin or Carboplatin|DRUG: Pemetrexed|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Bevacizumab|DRUG: Renvastinib|DRUG: AWT020
DLT rate, DLT rate, Up to approximately 12 months from first patient in|AE, Safety endpoint: incidence and severity of AE, abnormal changes in clinically significant laboratory and other tests, Up to approximately 12 months from first patient in|SAE, Safety endpoint: incidence and severity of SAE, abnormal changes in clinically significant laboratory and other tests, Up to approximately 12 months from first patient in|MTD, Determine maximum tolerated dose, Up to approximately 12 months from first patient in|RP2D, Recommended phase II dose (RP2D) for AWT020 monotherapy and combination therapy, Up to approximately 32 months from first patient in
Drug concentrations, Drug concentrations in individual subjects at different time points after dosing, Up to approximately 24 months from first patient in|Immunogenicity, Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples, Up to approximately 24 months from first patient in|ORR, Efficacy endpoint: Objective response rate(ORR) per RECIST v1.1, Up to approximately 32 months from first patient in|DOR, Efficacy endpoint: Duration of response (DOR) per RECISIT v1.1, Up to approximately 32 months from first patient in|DCR, Efficacy endpoint: Disease control rate (DCR) per RECISIT v1.1, Up to approximately 32 months from first patient in|PFS, Efficacy endpoint: Progress -free survival (PFS) per RECISIT v1.1, Up to approximately 32 months from first patient in|OS, Efficacy endpoint: Overall survival (OS), Up to approximately 32 months from first patient in
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies